Crystal structure of the c-abl kinase domain (cyan) in complex with imatinib (coloured orange). Imatinib (Gleevec) blocks the activity of Abelson cytoplasmic tyrosine kinase (c-Abl), c-Kit and the platelet-derived growth factor receptor (PDGFR). As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans. Model based on Protein Database entry 1IEP. | |
Licence : | Droits gérés |
Crédit: | Science Photo Library / Camazine, Scott |
Taille de l’image : | 4700 px × 3697 px |
Model Release : | Non requis |
Property Release : | Non requis |
Restrictions : | - |